Imodium Plus

Dimeticone and Loperamide Hydrochloride, the active ingredients in Imodium Plus, are an antidiarrheal and anti‑foaming agent presented as an oral dosage form for oral use. They provide symptomatic relief of acute nonspecific diarrhea, traveler’s diarrhea, and gastrointestinal gas and bloating in adults and children.

GNH USA supplies Imodium Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Imodium Plus, an antidiarrheal and anti‑foaming combination, is indicated for conditions that involve increased intestinal motility or excess gastrointestinal gas.

- Acute nonspecific diarrhea: reduces stool frequency and liquidity, providing rapid symptom control in adults and children experiencing sudden onset watery stools. - Traveler’s diarrhea: helps manage loose stools and abdominal discomfort during travel, allowing continuation of daily activities while the underlying infection resolves. - Gastrointestinal gas and bloating: dimeticone lowers surface tension of gas bubbles, promoting coalescence and easier expulsion, thereby relieving abdominal distension and discomfort.

Imodium Plus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Constipation: decreased bowel movements that may produce hard, dry stools and a feeling of incomplete evacuation. - Abdominal cramps: intermittent stomach pain or tightening that is usually mild and resolves after a short period. - Nausea: sensation of queasiness that can occur shortly after taking the medication, often without vomiting. - Dizziness: transient light‑headedness or unsteady feeling, particularly when standing up quickly.

Serious or Rare Side Effects: - Severe constipation or intestinal obstruction: persistent inability to pass stool accompanied by abdominal distension, requiring prompt medical evaluation. - Allergic reactions: skin rash, itching, swelling of the face, lips or throat, and in rare cases, difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm that has been reported with high‑dose or misuse of loperamide. - Toxic megacolon: a rare, life‑threatening enlargement of the colon that presents with severe abdominal pain, fever and systemic toxicity.

When using Imodium Plus, several precautions should be observed to minimize risks and ensure appropriate therapy. - Do not exceed the recommended dose: higher amounts increase the risk of severe constipation and cardiac effects. - Use caution in hepatic impairment: loperamide is metabolized by the liver and may accumulate. - Avoid in children under two years: safety and efficacy have not been established for this age group. - Do not use if fever or blood in stool is present: these may indicate infection requiring other treatment. - Concomitant use with other antidiarrheals: may lead to excessive slowing of gut motility. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Imodium Plus can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Opioid agonists (e.g., codeine): combined effect may cause profound constipation and risk of ileus. - Strong CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): increase loperamide plasma levels, raising toxicity risk. - Anticholinergic agents (e.g., diphenhydramine): additive reduction of intestinal motility leading to severe constipation. - MAO inhibitors: may potentiate central opioid effects, though rare with oral loperamide.

Moderate Interactions (Monitor Closely): - Other antidiarrheal agents (e.g., bismuth subsalicylate): may enhance antidiarrheal effect and increase constipation risk. - Azole antifungals (e.g., ketoconazole, itraconazole): moderate CYP3A4 inhibition can raise loperamide concentrations. - Selective serotonin reuptake inhibitors (e.g., sertraline): may affect gastrointestinal motility and require monitoring.